Logos Global Management’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Logos Global Management’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-137,500	Closed	-$6.6M	–	71
2021 Q4	$6.6M	Sell	137,500 -3,000	-2%	-$315K	0.68%	35
2021 Q3	$20.5M	Buy	140,500 +50,589	+56%	+$6.57M	1.48%	22
2021 Q2	$10.4M	Buy	89,911 +16,511	+22%	+$1.84M	0.87%	36
2021 Q1	$7.07M	Buy	+73,400	New	+$9.58M	0.69%	28

Other funds holding LABP

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Logos Global Management's LABP Position: Q1 2022 in Review

Logos Global Management sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q1 2022, closing a stake of 137,500 shares — an estimated $6.6M sold.

Logos Global Management first reported a position in LABP in Q1 2021 and held it in 4 quarters. The position peaked at $20.5M in Q3 2021. 45 funds tracked by Wall St. Rank hold LABP as of Q1 2022.

Logos Global Management reported no remaining Landos Biopharma, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Logos Global Management sold 137,500 Landos Biopharma, Inc. Common Stock shares in Q1 2022, an estimated $6.6M.
Logos Global Management first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Logos Global Management's Landos Biopharma, Inc. Common Stock position peaked at $20.5M in Q3 2021.
45 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q1 2022.

Based on Logos Global Management's 13F filing for Q1 2022, filed 16 May 2022.